Neuroscience & Biobehavioral Reviews
August 20, 2026
Lucy Chester, Heidar Sharafi, Amani Mahroug et al.
Research on the pharmacokinetic influence of cannabidiol (CBD) on delta-9-tetrahydrocannabinol (THC) has produced equivocal results. We conducted a systematic search following PRISMA guidelines (last search: 24th November 2025, PROSPERO: CRD42023480695). Included studies were acute dosing trials that administered a) a single, fixed dose of THC and b) a matched dose of THC co-administered with...
Journal of Psychopharmacology
July 15, 2026
Lucy Chester, François-Olivier Hebert, Pamela Lachance-Touchette et al.
BACKGROUND Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent. AIMS To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesised that 200 mg of CBD would produce a greater peak pleasant drug effect than a placebo. METHODS In a triple-blind,...
BMJ Open
March 1, 2026
Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.
BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...
Neuropsychopharmacology
November 1, 2023
Nicolas Garel, Kyle T. Greenway, Lê-Anh Dinh-Williams et al.
10 citations
We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none...
Journal of dual diagnosis
July 3, 2023
Benedikt Fischer, W. Hall, T. Fidalgo et al.
Abstract Objective: Cannabis use is increasingly normalized; psychosis is a major adverse health outcome. We reviewed evidence on cannabis use-related risk factors for psychosis outcomes at different stages toward recommendations for risk reduction by individuals involved in cannabis use. Methods: We searched primary databases for pertinent literature/data 2016 onward, principally relying on...
Drug and Alcohol Dependence
August 19, 2022
Nicolas Garel, Christina Mcanulty, Kyle T. Greenway et al.
33 citations
BACKGROUND: Alcohol use disorder is highly prevalent and has important economical, societal, psychiatric, and medical consequences. All currently approved therapeutic approaches targeting alcohol dependence have relatively modest effects and high relapse rates. Recent evidence suggests that ketamine may be an effective intervention to treat alcohol use disorder and alcoholic withdrawal. This...
Psychological Medicine
March 24, 2022
Tessa Robinson, Muhammad Usman Ali, Bethany Easterbrook et al.
61 citations
BACKGROUND: Epidemiological studies show a dose-response association between cannabis use and the risk of psychosis. This review aimed to determine whether there are identifiable risk-thresholds between the frequency of cannabis use and psychosis development. METHODS: Systematic search of Embase, MEDLINE, PsycINFO, CINAHL, and Web of Science for relevant studies (1 January 2010-26 April 2021)....
Paediatrics & Child Health
June 1, 2020
Clairélaine Ouellet-Plamondon, Simon Dubreucq, Didier Jutras-Aswad
2 citations
A 17-year-old male is brought to the emergency room by a friend who finds him strange lately. The patient is very anxious and seems to be scared. He reports having recently discovered that government was spying on him, using a complex network of cameras and satellites. He has unplugged all of his house hold electronic devices and refuses to talk to his friend on the phone. During the interview,...